RGEN as of Nov 2 · 05:07 ET
RGENNasdaqBiological Products, (No Diagnostic Substances)

Repligen Corp · Brief

Next report

113 days

Feb 23 · before openest.Q4 FY26

Expected move

No implied move.

Implied vs realized

8 reportsHistory
—≥ implied
Apr 29 '25—▼−2.92%—
Jul 29 '25—▲+4.72%—
Oct 28 '25—▼−5.92%—
Feb 24 '26—▼−0.54%—
Q1 FY26—▲+6.26%—
Q2 FY26—▲+2.26%—
Jul 28 '26—▲+10.90%—
Q3 FY26±11.7%▼−2.43%×0.21
quarterimplied−15%0+15%realized×
Q3 FY26±11.7%▼−2.43%×0.21
Jul '26—▲+10.90%—
Q2 FY26—▲+2.26%—
Q1 FY26—▲+6.26%—
Feb '26—▼−0.54%—
Oct '25—▼−5.92%—
2 older reports
Jul '25—▲+4.72%—
Apr '25—▼−2.92%—
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Feb 23 report · est.

—

Linked exposure

RGEN report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 13impliedImplied move: ±13.2% into Oct 27 earnings (Oct 13 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.